Novartis seeks legal action on eye drug
State-run hospitals could be forced to give $1,000 Lucentis injections instead of Avastin
The Associated Press
Posted: Apr 24, 2012 11:51 AM ET
Last Updated: Apr 24, 2012 11:37 AM ET
Drug maker Novartis is taking legal action in Britain to make state-run hospitals use an eye drug that costs about $1,120 per shot instead of a cheaper one that costs just $95.
In a statement, Novartis said it was calling for a judicial review "as a last resort" because it believed patient safety was being potentially compromised.Lucentis is recommended to treat the eye problem age-related macular degeneration. (CBC)
According to Britain's health watchdog, Novartis' Lucentis is the only drug recommended to treat the eye problem macular degeneration in the country's state-run National Health Service hospitals.
However, several NHS hospitals have been prescribing the much cheaper Avastin, a cancer drug made by Genentech Inc., for the same problem even though it has not been officially approved.
Last year, the Canadian Council of the Blind also said provincial governments should be funding the approved drug for age-related macular degeneration, Lucentis.
Since 2008, about 120 Canadians have had serious eye inflammation after receiving injections of Avastin, Dr. Alan Berger, ophthalmologist in chief at St. Michael's Hospital in Toronto, said at the time.
Most doctors only prescribe drugs approved by the health watchdog, but have the discretion to use other treatments if they believe they are warranted.
Last year, four hospitals in southern England decided they would pay for Avastin when it was prescribed by a doctor.
In a statement Tuesday, Novartis AG said it was demanding a judicial review to make the hospitals use Lucentis rather than Avastin.
Novartis said it was concerned patients and clinicians were being pushed to use an unlicensed medicine in order to cut costs.
Britain's coalition government has mandated that its National Health Service trim 20 billion pounds from its budget by 2015 as part of a national austerity drive.
"It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," the pharmaceutical company said.
Novartis noted there was "emerging evidence" of safety concerns for using Avastin to treat eye problems.
Patient groups called for an independent analysis to determine which drug should be used. "If Avastin is not as safe as Lucentis, no one should be using it," said Helen Jackman, chief executive of the Macular Disease Society. "If it is as good, perhaps everyone should be using it."
Jackman said government ministers should hold an appraisal of whether Avastin was safe to use in eye diseases. Eye doctors are divided over whether Avastin is as safe and effective as Lucentis, she said.
Other critics slammed Novartis for their decision to go to the courts.
"Companies like Novartis should not be in the position to block moves to more cost-effective treatments in order to maximize their profits," said John Harris, of the Institute for Science Ethics and Innovation at the University of Manchester, in a statement. He said it was legitimate for health providers to use treatments that were much cheaper than ones that were already licensed.
Top News Headlines
- 30,000 Canadians are homeless every night
- A new national report into homelessness in this country tells a grim story — at least 200,000 Canadians experience homelessness in any given year and least 30,000 Canadians are homeless on any given night. more »
- Obesity called a disease by U.S. doctors group
- In order to fight what it described as an "obesity epidemic," the American Medical Association voted to recognize obesity as a disease and recommended a number of measures to fight it. more »
- Neil Macdonald: Washington's obsession with leakers
- Julian Assange and Edward Snowden are just the most prominent targets in an all-out legal and propaganda campaign that America's security apparatus is mounting against leakers everywhere, Neil Macdonald writes. more »
- How open is Ottawa's new 'open data' website?
- Treasury Board President Tony Clement is touting the federal government's revamped data portal as a "new natural resource." But that online window for previously published data arrives at the same time the government faces controversy over just how open it really is. more »
Latest Health News Headlines
- Are e-cigarettes safe to puff?
- As electronic or e-cigarettes grow in popularity, some health advocates want them to be regulated. more »
- Fredericton teen attends prom despite serious allergies
- A Fredericton high school student went to her prom on Tuesday night, despite the threat that one waft of perfume could have serious consequences. more »
- Sexually transmitted oral cancers screened with early blood test
- Antibodies to a high-risk type of a virus that causes mouth and throat cancers when transmitted via oral sex can be detected in blood tests many years before onset of the disease, according to a World Health Organization-led team of researchers. more »
- Nunavummiut waiting up to a year for eye exams
- Unlike every other province and territory in Canada, Nunavut does not have its own optometrist or ophthalmologist. That's causing a wait time of up to a year for many of the territory's residents. more »
- 2 men jailed in Dominican wedding fight back in Canada
- Bob Rae stepping down as an MP
- Half of First Nations children live in poverty
- All-party deal on bills, MP oversight lets House out early
- Are e-cigarettes safe to puff?
- Huge ancient city at Angkor Wat revealed by lasers
- Tim Hortons being circled by Wall Street hedge funds
- B.C. teacher duct-taped students' mouths
- Most groups don't want return of Trudeau speaking fees